NCT07823452Not yet recruitingPhase 2
Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
Glucagon-like peptide (GLP1) drugs have quickly become a standard treatment for the adults with obesity. These drugs target the appetite control center of the brain, which clows the rate of stomach emptying, and makes a person feel full. The researchers are exploring this response in children. This study is being conducted to better understand how two food carbohydrates affect the appetite control center of the brain. The investigators want to see if a special carbohydrate powder that is mixed with 1 cup of water twice a day will appetite.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 3 Sept 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Indiana University
- Diseases
- Obesity
- NCT number
- NCT07823452
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 62
- From 1 Jan 2027 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Children with any intestinal resection
- Children taking any medications or supplements for weight loss within 30 days prior to enrollment in the study
Other illness
- Children with malabsorptive disorders including inflammatory bowel disease, Celiac disease, and short bowel syndrome
- Children with Type 1 or Type 2 Diabetes Mellitus
- Subject has any condition that, in the opinion of the investigator, would compromise the well-being of the subject or would compromise the study or prevent the subject from meeting or performing study requirements.
Other
- Females who are or planning to become pregnant or are breastfeeding
Who the study is looking for
- Children ages 12 to ≤18 years and older with obesity, a BMI ≥95% for age and sex
- English-speaking subjects
- Children who have been on stable dosing of medications for 3 months which secondarily lead to weight gain, weight loss, or appetite suppression
- Children able to stay on a stable dose of all concomitant medications throughout the study treatment period
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Riley Hospital for Children at IU Health Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.